Zoledronic acid linked to early increase in sclerostin levels

April 29, 2013
Zoledronic acid linked to early increase in sclerostin levels
Women with postmenopausal osteoporosis treated with zoledronic acid show an early increase in serum levels of the negative regulator of bone formation, sclerostin, that return close to baseline after 360 days, according to a study published online April 17 in the Journal of Clinical Endocrinology & Metabolism.

(HealthDay)—Women with postmenopausal osteoporosis treated with zoledronic acid show an early increase in serum levels of the negative regulator of bone formation, sclerostin, that return close to baseline after 360 days, according to a study published online April 17 in the Journal of Clinical Endocrinology & Metabolism.

Antonino Catalano, M.D., Ph.D., from the University of Messina in Italy, and colleagues randomized 40 women (mean age, 62.6 years) with postmenopausal to receive 5 mg zoledronic acid or placebo. of sclerostin, bone specific alkaline phosphatase (BSAP; marker of bone formation), and serum C-telopeptide of type 1 collagen (CTX; marker of bone resorption), were measured at baseline and after two, seven, 30, and 360 days.

The researchers found that, for those taking zoledronic acid, sclerostin serum levels had already increased at day two. These levels peaked at three-fold baseline at day seven; decreased at day 30; and returned close to baseline after 360 days. In the zoledronic acid group, CTX and BSAP were reduced at all time points. In addition, at all time points a significant negative correlation between the percentage changes of sclerostin and the variation of BSAP and CTX was observed. There were no changes in the placebo group.

"Our data demonstrate that increases sclerostin serum levels and sclerostin could play a role in coupling bone resorption to ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Once-yearly zoledronic acid benefits men with osteoporosis

November 2, 2012

(HealthDay)—For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. ...

Sclerostin linked to vascular disease in type 2 diabetes

January 28, 2013

(HealthDay)—Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes ...

Common osteoporosis drug slows formation of new bone

April 17, 2013

Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.